Hmn-147 [2021]

HMN-147 is currently in the early stages of clinical development, with several ongoing studies evaluating its safety, efficacy, and pharmacokinetics in patients with various types of cancer. These studies aim to determine the optimal dosing regimen, identify potential side effects, and assess the therapeutic potential of HMN-147.

In the lexicon of contemporary transhumanist discourse, acronyms such as , CORTEX‑X , and NEURO‑LINK have come to symbolize incremental steps toward augmenting human cognition. HMN‑147 , however, marks a qualitative shift: it is the first project that claims to embed programmable silicon directly within the genome of living cells, thereby allowing a living organism to execute digital algorithms as part of its innate physiological processes. The “HMN” prefix stands for Human‑Machine Nexus , while “147” denotes the internal project code used by the consortium that originally funded the research (the 147th grant awarded by the International Frontier Science Initiative). HMN-147

To understand the potential of HMN-147, it's essential to delve into the biology of AXL and its role in cancer. AXL is a receptor tyrosine kinase that is overexpressed in various types of cancer, including breast, lung, and pancreatic cancer. When AXL binds to its ligand, growth arrest-specific protein 6 (Gas6), it triggers a cascade of downstream signaling events that promote cell proliferation, migration, and survival. HMN-147 is currently in the early stages of

In the 2025 Seminary Teacher Manual, HMN-147 serves as a teaching block to help students: HMN‑147 , however, marks a qualitative shift: it

Beyond cognition, HMN‑147 demonstrated . By embedding a GEC motif that senses blood glucose levels and drives insulin release via a silicon‑mediated exocytosis trigger, the consortium created a self‑regulating diabetic model in mice. The system adjusted insulin output with a latency of < 200 ms, outperforming conventional closed‑loop insulin pumps. This suggests a future in which bio‑electronic implants could become autonomous organ‑level regulators .

HMN-147 is a small molecule inhibitor that belongs to a class of drugs known as tyrosine kinase inhibitors. Specifically, it targets the AXL receptor tyrosine kinase, which plays a crucial role in the progression and metastasis of various types of cancer. By inhibiting AXL, HMN-147 aims to disrupt the signaling pathways that promote cancer cell growth, migration, and survival.